184 related articles for article (PubMed ID: 23436265)
1. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
3. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
Königs C; Feiterna-Sperling C; Esposito S; Viscoli C; Rosso R; Kakuda TN; Leemans R; Peeters M; Mack R; Peeters I; Sinha R; Boven K; Giaquinto C
AIDS; 2012 Feb; 26(4):447-55. PubMed ID: 22156961
[TBL] [Abstract][Full Text] [Related]
5. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
[TBL] [Abstract][Full Text] [Related]
8. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
9. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
[TBL] [Abstract][Full Text] [Related]
11. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.
Ng J; Chiu YL; Awni W; Bernstein B; Causemaker SJ; Klein CE
J Clin Pharmacol; 2012 Aug; 52(8):1248-54. PubMed ID: 21719718
[TBL] [Abstract][Full Text] [Related]
13. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.
Ramanathan S; Kakuda TN; Mack R; West S; Kearney BP
Antivir Ther; 2008; 13(8):1011-7. PubMed ID: 19195326
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
[TBL] [Abstract][Full Text] [Related]
17. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Kakuda TN; Abel S; Davis J; Hamlin J; Schöller-Gyüre M; Mack R; Ndongo N; Petit W; Ridgway C; Sekar V; Tweedy S; Hoetelmans RM
Antimicrob Agents Chemother; 2011 May; 55(5):2290-6. PubMed ID: 21383098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
